ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

被引：0
|
作者：
Essers, B. A. [1 ]
Tjan, Heijnen, V [1 ]
Severens, J. L. [1 ]
Novak, A. [2 ]
Oron, U. [3 ]
Pompen, M. [4 ]
Joore, M. A. [1 ]
机构：
[1] Univ Hosp Maastricht, Maastricht, Netherlands
[2] Anovak Serv, Apeldoorn, Netherlands
[3] Roche, Woerden, Netherlands
[4] Roche Netherland BV, Woerden, Netherlands
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66577-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A472 / A472
页数：1
相关论文
共 50 条
  • [21] ADJUVANT TC (DOCETAXEL/CYCLOPHOSPHAMIDE)-HER (TRASTUZUMAB) (TC-HER) IN HER2 POSITIVE BREAST CANCER
    Hara, F.
    Kiyoto, S.
    Takahashi, M.
    Takabatake, D.
    Takashima, S.
    Aogi, K.
    Ohsumi, S.
    BREAST, 2013, 22 : S87 - S87
  • [22] Adjuvant Treatment of HER2 Positive Breast Cancer: The Next Installment
    Pietenpol, J. A.
    CANCER RESEARCH, 2012, 72
  • [23] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [24] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [25] Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    DRUGS, 2010, 70 (02) : 215 - 239
  • [26] Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer
    Reed, Shelby D.
    Schulman, Kevin A.
    VALUE IN HEALTH, 2009, 12 (05) : 637 - 640
  • [27] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [28] A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Kurian, Allison W.
    Newton Thompson, Rebecca
    Gaw, Allison F.
    Arai, Sally
    Ortiz, Rafael
    Garber, Alan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 634 - 641
  • [29] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [30] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
12345